Pushing the boundaries of siRNA targeting and delivery

Nucleic Acid Insights 2024; 1(3), 115–119

DOI: 10.18609/nai.2024.016

Published: 20 March
Merle Fuchs

Although siRNA therapeutics have made significant progress in terms of their stability and safety, key challenges relating to the specificity and efficiency of delivery remain. David McCall, Senior Editor, BioInsights, talks to Merle Fuchs, Co-Founder and CEO of PRAMOMOLECULAR GmbH, about promising approaches to address this issue and continue expanding the range of applications available to oligonucleotide therapeutics.